AcquisitionsOct 19, 2026, 04:51 PM
Vivos Therapeutics Acquires 11% Stake in SOD Sciences, 50% Test Interest
AI Summary
Vivos Therapeutics, Inc. has completed the acquisition of an 11% equity interest in SOD Sciences, Inc. and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test. In exchange, Vivos issued 12,000 shares of Series C Convertible Preferred Stock with a stated value of $12 million. This transaction is expected to add over $10 million to Vivos' stockholders' equity and potentially provide access to over 325,000 new patients through SOD's marketing relationships. Vivos believes this acquisition could be a transformational event, expanding its market and services for patients at risk for OSA and related chronic diseases.
Key Highlights
- Vivos Therapeutics closed acquisition of an 11% stake in SOD Sciences and 50% interest in pseudohypoxia test.
- Vivos issued 12,000 shares of Series C Convertible Preferred Stock with an aggregate stated value of $12 million to SOD.
- The transaction is expected to add more than $10 million to Vivos' stockholders' equity.
- Vivos gains potential access to over 325,000 new patients through SOD's relationship with American Health Associates (AHA).
- The Series C Preferred Stock is convertible at $0.15 per share into up to 80,000,000 shares of common stock, subject to caps.
- Vivos and SOD will share equally all revenue and costs derived from the exploitation of the Test IP.
- Vivos expects to record the SOD interest and test interest as assets at fair value, potentially regaining Nasdaq equity compliance.
Price Impact
More from VVOS